8-K: Aadi Bioscience Extends Supply Agreement with Fresenius Kabi

Aadi Bioscience has extended its supply agreement with Fresenius Kabi for FYARRO, modifying terms related to pricing, forecasting, and minimum purchase obligations.

Summary

• Aadi Bioscience, Inc. has amended its agreement with Fresenius Kabi, LLC, effective March 31, 2024.
• The amendment extends the agreement's term until July 31, 2024, or a later date if agreed upon by both parties.
• The amendment includes revisions to pricing, forecasting, compliance, and Aadi's minimum purchase obligations for FYARRO.
• The agreement also contains standard terms for manufacturing therapeutics in the biotechnology industry.

Sentiment

Score: 7

Explanation: The document indicates a positive development with the extension of a key supply agreement, but the lack of specific financial details prevents a higher score.

Positives

• The extension of the supply agreement ensures continued access to FYARRO for Aadi Bioscience.
• The revised terms may provide more favorable conditions for Aadi Bioscience.

Risks

• The specific details of the revised pricing and minimum purchase obligations are not disclosed, which could impact Aadi's financial performance.
• The agreement is only extended until July 31, 2024, requiring further negotiation or a new agreement in the near future.

Future Outlook

The agreement is extended until July 31, 2024, with the possibility of further extension, indicating continued collaboration between Aadi Bioscience and Fresenius Kabi.

Industry Context

This agreement is typical for biotechnology companies that rely on contract manufacturers for their products, ensuring a stable supply chain for their therapeutics.

Comparison to Industry Standards

• Many biotech companies rely on contract manufacturing organizations (CMOs) like Fresenius Kabi to produce their drugs.
• The terms of these agreements often include minimum purchase obligations and pricing adjustments based on volume and market conditions.
• Extending supply agreements is a common practice to ensure continuity of supply and avoid disruptions in the market.

Stakeholder Impact

• Shareholders may view the extension positively as it ensures continued supply of FYARRO.
• Employees can expect continued operations related to FYARRO.
• Customers will have continued access to the therapeutic.

Next Steps

• Aadi Bioscience will file the full amendment as an exhibit in a subsequent periodic report.
• Aadi Bioscience and Fresenius Kabi may need to negotiate a new agreement or further extension before July 31, 2024.

Key Dates

Keywords

Aadi Bioscience, Fresenius Kabi, FYARRO, supply agreement, contract extension, pharmaceuticals, biotechnology, manufacturing, clinical product, commercial product